Peng B - Search Results

1

Population pharmacokinetics of carboplatin in children.

Chatelut E, Boddy AV, Peng B, Rubie H, Lavit M, Dezeuze A, Pearson AD, Roché H, Robert A, Newell DR, Canal P. Chatelut E, et al. Among authors: peng b. Clin Pharmacol Ther. 1996 Apr;59(4):436-43. doi: 10.1016/S0009-9236(96)90113-7. Clin Pharmacol Ther. 1996. PMID: 8612389 Clinical Trial.

2

Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients.

Peng B, Boddy AV, Cole M, Pearson AD, Chatelut E, Rubie H, Newell DR. Peng B, et al. Eur J Cancer. 1995 Oct;31A(11):1804-10. doi: 10.1016/0959-8049(95)00382-s. Eur J Cancer. 1995. PMID: 8541105

3

Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis.

English MW, Lowis SP, Peng B, Boddy A, Newell DR, Price L, Pearson AD. English MW, et al. Among authors: peng b. Br J Cancer. 1996 Mar;73(6):776-80. doi: 10.1038/bjc.1996.135. Br J Cancer. 1996. PMID: 8611379 Free PMC article.

4

Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.

Peng B, Tilby MJ, English MW, Price L, Pearson AD, Boddy AV, Newell DR. Peng B, et al. Br J Cancer. 1997;76(11):1466-73. doi: 10.1038/bjc.1997.579. Br J Cancer. 1997. PMID: 9400943 Free PMC article.

5

Cisplatin pharmacokinetics in children with cancer.

Peng B, English MW, Boddy AV, Price L, Wyllie R, Pearson AD, Tilby MJ, Newell DR. Peng B, et al. Eur J Cancer. 1997 Oct;33(11):1823-8. doi: 10.1016/s0959-8049(97)00341-9. Eur J Cancer. 1997. PMID: 9470840

6

Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study.

Schmidli H, Peng B, Riviere GJ, Capdeville R, Hensley M, Gathmann I, Bolton AE, Racine-Poon A; IRIS Study Group. Schmidli H, et al. Among authors: peng b. Br J Clin Pharmacol. 2005 Jul;60(1):35-44. doi: 10.1111/j.1365-2125.2005.02372.x. Br J Clin Pharmacol. 2005. PMID: 15963092 Free PMC article. Clinical Trial.

7

Effect of hepatic or renal impairment on eltrombopag pharmacokinetics.

Bauman JW, Vincent CT, Peng B, Wire MB, Williams DD, Park JW. Bauman JW, et al. Among authors: peng b. J Clin Pharmacol. 2011 May;51(5):739-50. doi: 10.1177/0091270010372106. Epub 2010 Jul 27. J Clin Pharmacol. 2011. PMID: 20663991 Clinical Trial.

8

Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion.

Peng B, Dutreix C, Mehring G, Hayes MJ, Ben-Am M, Seiberling M, Pokorny R, Capdeville R, Lloyd P. Peng B, et al. J Clin Pharmacol. 2004 Feb;44(2):158-62. doi: 10.1177/0091270003262101. J Clin Pharmacol. 2004. PMID: 14747424 Clinical Trial.

9

Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers.

Matthys G, Park JW, McGuire S, Wire MB, Bowen C, Williams D, Jenkins J, Peng B. Matthys G, et al. Among authors: peng b. J Clin Pharmacol. 2011 Mar;51(3):301-8. doi: 10.1177/0091270010368677. Epub 2010 Apr 23. J Clin Pharmacol. 2011. PMID: 20418510 Clinical Trial.

10

Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group.

Judson I, Ma P, Peng B, Verweij J, Racine A, di Paola ED, van Glabbeke M, Dimitrijevic S, Scurr M, Dumez H, van Oosterom A. Judson I, et al. Among authors: peng b. Cancer Chemother Pharmacol. 2005 Apr;55(4):379-386. doi: 10.1007/s00280-004-0876-0. Epub 2004 Dec 9. Cancer Chemother Pharmacol. 2005. PMID: 15592836

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,953 results

Search Page